HIV-1 Vpu enhances the release of virions from infected cells by overcoming a cellular inhibitor that retains nascent virions within and on infected cells. The identity of this inhibitor has recently been revealed: it is the transmembrane, GPI-anchored protein BST-2, also known as HM1.24, CD317, or "tetherin." BST-2 seems able to affect diverse enveloped virions, suggesting a broad role in the host defense against viruses including HIV-1. The research proposed here has three specific aims: 1) to reveal how BST-2 retains HIV-1 virions on infected cells;2) to determine how Vpu antagonizes this restriction;3) to understand the regulation of BST-2 during the innate immune response and to explore the potential function of BST-2 in antigen presenting cells.
These aims will be pursued using a concerted experimental approach including targeted mutagenesis of BST-2 and Vpu, characterization of the interaction between BST-2 and Vpu, analysis of the effects of Vpu on the intracellular trafficking and virion-incorporation of BST-2, and analysis of the regulation and function of BST-2 in primary T lymphocytes and antigen presenting cells. When these aims are completed, we will know how BST-2 retains virions on infected cells, how Vpu counteracts this protein, how BST-2 is regulated during the innate immune response, and whether it plays a role in the uptake of virions by antigen presenting cells during the adaptive immune response.

Public Health Relevance

BST-2 is a newly identified host-cell protein that retains virus particles including those of HIV-1 on infected cells. The HIV-1 protein Vpu counteracts this host defense. This research is designed to explore how BST-2 retains virus particles, how Vpu antagonizes this activity, and how BST-2 is regulated within primary cells of the immune system.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-AARR-A (02))
Program Officer
Sharma, Opendra K
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Veterans Medical Research Fdn/San Diego
San Diego
United States
Zip Code
Abdel-Mohsen, Mohamed; Deng, Xutao; Liegler, Teri et al. (2014) Effects of alpha interferon treatment on intrinsic anti-HIV-1 immunity in vivo. J Virol 88:763-7
Jafari, Moein; Guatelli, John; Lewinski, Mary K (2014) Activities of transmitted/founder and chronic clade B HIV-1 Vpu and a C-terminal polymorphism specifically affecting virion release. J Virol 88:5062-78
Tokarev, Andrey; Suarez, Marissa; Kwan, Wilson et al. (2013) Stimulation of NF-ýýB activity by the HIV restriction factor BST2. J Virol 87:2046-57
Pillai, Satish K; Abdel-Mohsen, Mohamed; Guatelli, John et al. (2012) Role of retroviral restriction factors in the interferon-?-mediated suppression of HIV-1 in vivo. Proc Natl Acad Sci U S A 109:3035-40
Skasko, Mark; Wang, Yan; Tian, Ye et al. (2012) HIV-1 Vpu protein antagonizes innate restriction factor BST-2 via lipid-embedded helix-helix interactions. J Biol Chem 287:58-67
Tokarev, Andrey A; Munguia, Jason; Guatelli, John C (2011) Serine-threonine ubiquitination mediates downregulation of BST-2/tetherin and relief of restricted virion release by HIV-1 Vpu. J Virol 85:51-63
Homann, Stefanie; Smith, Davey; Little, Susan et al. (2011) Upregulation of BST-2/Tetherin by HIV infection in vivo. J Virol 85:10659-68
Skasko, Mark; Tokarev, Andrey; Chen, Cheng-Chang et al. (2011) BST-2 is rapidly down-regulated from the cell surface by the HIV-1 protein Vpu: evidence for a post-ER mechanism of Vpu-action. Virology 411:65-77
Lau, David; Kwan, Wilson; Guatelli, John (2011) Role of the endocytic pathway in the counteraction of BST-2 by human lentiviral pathogens. J Virol 85:9834-46
Ruiz, Autumn; Guatelli, John C; Stephens, Edward B (2010) The Vpu protein: new concepts in virus release and CD4 down-modulation. Curr HIV Res 8:240-52

Showing the most recent 10 out of 19 publications